|Other Names||Folate receptor gamma, FR-gamma, Folate receptor 3, FOLR3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13617a was selected from the N-term region of FOLR3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform Short does not bind folate.|
|Tissue Location||Spleen, thymus, bone marrow, ovarian carcinoma, and uterine carcinoma|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the folate receptor (FOLR)family, members of which have a high affinity for folic acid andfor several reduced folic acid derivatives, and mediate delivery of5-methyltetrahydrofolate to the interior of cells. This geneincludes two polymorphic variants; the shorter one has two basedeletion in the CDS, resulting in a truncated polypeptide, comparedto the longer one. Both protein products are constitutivelysecreted in hematopoietic tissues and are potential serum markerfor certain hematopoietic malignancies. The longer protein has a71% and 79% sequence homology with the FOLR1 and FOLR2 proteins,respectively.
O'Byrne, M.R., et al. Birth Defects Res. Part A Clin. Mol. Teratol. 88(8):689-694(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :Boyles, A.L., et al. Genet. Epidemiol. 33(3):247-255(2009)Franke, B., et al. Birth Defects Res. Part A Clin. Mol. Teratol. 85(3):216-226(2009)Hillman, R.T., et al. Genome Biol. 5 (2), R8 (2004) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.